Drug Trial Radar · NCT01646437
The International Polycap Study 3 (TIPS-3)
Last checked: Nov 20, 2026Latest source record: Sep 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,793
Actual
Start
Jun 2012
Primary completion
Jun 30, 2020
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- Population Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cadila Pharnmaceuticals; Wellcome Trust; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Ontario
- First posted
- Jul 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The randomized 2x2x2 factorial design placebo controlled trial will enroll 5000 participants (women 60 years or older and men 55 years or older) without known heart disease or prior stroke and without a clear indication or contraindication to any of the study medications. Eligible and consenting individuals will be randomized to receive either the active study medications or placebo (dummy pills) and will be monitored for an average of 5 years. The study will include people from at 10 countries, will be conducted by an international group of scientists and physicians and will be coordinated by the Population Health Research Institute at Hamilton Health Sciences.
Conditions
- Cardiovascular Disease
- Fractures
- Cancers
Interventions
PolycapDrug
Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
AspirinDrug
75 mg daily
Vitamin DDrug
60,000 IU monthly
Matching PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Polycap Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
- Aspirin Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
- Vitamin D Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
- Combined Effects of Polycap and Aspirin on CVD EventsTime frame: Participants will be followed for an average of 4.25 years
Locations
9 sites in 9 countries. Site status is shown where the registry gives one.
Eminence
Dhaka, Bangladesh
Hamilton Health Sciences
Hamilton, Ontario, Canada
Fundaction Oftamologica De Santander (FOSCAL)
Bucaramanga, Colombia
St. John's Medical College Hospital
Bangalore, India
Harapan Kita Hopsital
Jakarta, Indonesia
Universiti Teknologi MARA (UiTM)
Shah Alam, Selangor, Malaysia
Adult Medicine & Medical Research Unit, Philippine General Hospital
Manila, Philippines
Pamoja Tunaweza Women's Centre
Moshi, Tanzania
Fattouma Bourguiba University Hospital
Monastir, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.